Naoko Takebe MD PhD - Bethesda ...

Dr. Naoko Takebe

Claim this profile

National Institutes of Health Clinical Center

Studies Pancreatic Cancer
Studies Cancer
7 reported clinical trials
13 drugs studied

Area of expertise

1Pancreatic Cancer
Naoko Takebe has run 4 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
PIK3CB positive
PTEN positive
2Cancer
Naoko Takebe has run 4 trials for Cancer. Some of their research focus areas include:
Stage IV
PIK3CB positive
PTEN positive

Affiliated Hospitals

Image of trial facility.
National Institutes Of Health Clinical Center
Image of trial facility.
National Cancer Institute Developmental Therapeutics Clinic

Clinical Trials Naoko Takebe is currently running

Image of trial facility.

Pelcitoclax + Cobimetinib

for Recurrent Ovarian and Endometrial Cancers

This trial tests the safety and best dose of two drugs, pelcitoclax and cobimetinib, in patients with recurring ovarian and endometrial cancers. Pelcitoclax helps kill cancer cells, and cobimetinib slows their growth. The goal is to find an effective dose and observe how well the combination works in shrinking or stabilizing tumors.
Recruiting1 award Phase 117 criteria
Image of trial facility.

CA-4948 + Chemotherapy

for Pancreatic Cancer

This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.
Recruiting1 award Phase 120 criteria

More about Naoko Takebe

Clinical Trial Related8 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Naoko Takebe has experience with
  • Nivolumab
  • Ipilimumab
  • Atezolizumab
  • Tiragolumab
  • Docetaxel
  • PI3Kbeta Inhibitor AZD8186

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Naoko Takebe specialize in?
Is Naoko Takebe currently recruiting for clinical trials?
Are there any treatments that Naoko Takebe has studied deeply?
What is the best way to schedule an appointment with Naoko Takebe?
What is the office address of Naoko Takebe?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security